Author

Joseph A. Rininger

Observed names: J. Rininger, Joseph A Rininger, Joseph Rininger

Institution: Eloxx Pharmaceuticals (United States)

Observed institutions: Cornell University, Eloxx Pharmaceuticals (United States), New York State College of Veterinary Medicine

OpenAlex ID: A5074448005

Immunopharmacological activity ofEchinaceapreparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells

2000 · Joseph A Rininger, Shirley Kickner, et al. · Journal of Leukocyte Biology · 152

Adjuvant solution for pandemic influenza vaccine production

2012 · Christopher H. Clegg, Richard Roque, et al. · Proceedings of the National Academy of Sciences · 73

Comparative Glycomics Analysis of Influenza Hemagglutinin (H5N1) Produced in Vaccine Relevant Cell Platforms

2013 · Yanming An, Joseph A. Rininger, et al. · Journal of Proteome Research · 64

Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

2012 · Elena Feshchenko, David G Rhodes, et al. · BMC Biotechnology · 48

GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza

2014 · Christopher H. Clegg, Richard Roque, et al. · PLoS ONE · 42

Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats

1997 · J. Rininger · Carcinogenesis · 37

Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity

2000 · Joseph A. Rininger, Vincent A. DiPippo, et al. · Drug Discovery Today · 34

Clinical vaccine development for H5N1 influenza

2013 · Christopher H Clegg, Joseph A Rininger, et al. · Expert Review of Vaccines · 31

A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells

2008 · Nathalie Bonafé, Joseph A. Rininger, et al. · Vaccine · 29

Discordant Hepatic Expression of the Cell Division Control Enzyme p34 Kinase, Proliferating Cell Nuclear Antigen, p53 Tumor Suppressor Protein, and p21 Cyclin-Dependent Kinase Inhibitory Protein after WY14,643 ([4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]Acetic Acid) Dosing to Rats

1997 · Xinfang Ma, Dana A. Stoffregen, et al. · Molecular Pharmacology · 19

Discordant expression of the cyclin-dependent kinases and cyclins in rat liver following acute administration of the hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643)

1996 · Joseph A. Rininger, Geoffrey D. Wheelock, et al. · Biochemical Pharmacology · 16

Murine hepatic p53, RB, and CDK inhibitory protein expression following acute 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure

1997 · Joseph A. Rininger, Dana A. Stoffregen, et al. · Chemosphere · 15

Characterization of a Recombinant Influenza Vaccine Candidate Using Complementary LC-MS Methods

2011 · Hongwei Xie, Catalin Doneanu, et al. · Current Pharmaceutical Biotechnology · 10

Staking out novelty on the genomic frontier

2002 · Kerry E Quinn-Senger, Ravi Ramachandran, et al. · Current Opinion in Chemical Biology · 6

Plant-Based Antibody Manufacturing

2023 · Gregory P. Pogue, Kelsi Swope, et al. · Concepts and strategies in plant sciences · 1

Correction to: Plant-Based Antibody Manufacturing

2024 · Gregory P. Pogue, Kelsi Swope, et al. · Concepts and strategies in plant sciences

Applying Predictive Toxicogenomic Markers to Screen Compounds for Liver Toxicity (TOXICOGENOMICS AND TOXICOPROTEOMICS) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)

2003 · Joseph A. Rininger, Oswald Crasta, et al. · The Journal of Toxicological Sciences

Works count: 18

Citation count: 577

H-index: 12

I10-index: 13